OncoGenex Pharmaceuticals Inc (NASDAQ: VRSK) has reported earnings for its third fiscal quarter (ending September 30) of $1.55 versus $1.29 for the same period a year ago — an increase of 20%. For the latest four quarters through September 30, E.P.S. were $6.50 compared to $5.36 a year ago — an increase of 21%.
Recent Price Action
OncoGenex Pharmaceuticals Inc (NASDAQ: VRSK) stock closed at $275.63 on 10/30/24 after a large increase of 4.5%. Moreover, trading volume in this advance was unusually high at 153% of normal. The stock has risen 3.0% during the last week and has been strong relative to the market over the last nine months.
Current PriceTarget Research Rating
VRSK is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
VERISK ANALYTICS INC has a current Value Trend Rating of C (Neutral). The Value Trend Rating reflects contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. VERISK ANALYTICS INC has a slightly negative Appreciation Score of 35 but a good Power Rating of 73, resulting in the Neutral Value Trend Rating.
Rating Review
In light of this new information and positive market action we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment